Abstract
Updated data from the phase II NADIM trials indicate that combining neoadjuvant nivolumab with chemotherapy benefits patients with operable non-small cell lung cancer, boosting rates of pathologic complete response as well as progression-free and overall survival. RNA sequencing may also have uncovered biomarkers that could better pinpoint patients at high risk of disease progression despite treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
